Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

8.8K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.8K
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

228
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
228
Preclinical Development: Overview01:28

Preclinical Development: Overview

4.8K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
4.8K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

1.1K
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
1.1K
Pharmacokinetic Models: Overview01:20

Pharmacokinetic Models: Overview

1.2K
Pharmacokinetic models utilize mathematical analysis to achieve a detailed quantitative understanding of a drug's life cycle within the body. They are instrumental in simulating a drug's pharmacokinetic parameters, predicting drug concentrations over time, optimizing dosage regimens, linking concentrations with pharmacologic activity, and estimating potential toxicity.
There are three primary types of models: empirical, compartment, and physiological. Empirical models, with minimal...
1.2K
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

128
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
128

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same authorSame journal

Current State-of-the-Art and Future Advancements of Model-Based Meta-Analysis.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Population Pharmacokinetics and Exposure-Response Analysis of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Beyond Impossibility: Reimagining Clinical Evidence for Children with Ultra-Rare Diseases.

Journal of clinical pharmacology·2026
Same author

Farnesyl transferase inhibitor KO-2806 (darlifarnib) enhances the anti-tumor activity of tyrosine kinase inhibitors in RCC.

Molecular cancer therapeutics·2026
Same author

Model-Based Patient Selection and Dosing Strategies for HRAS and PIK3CA Dysregulated HNSCC: A QSP Model for Alpelisib and Tipifarnib Combination.

Clinical pharmacology and therapeutics·2026
Same author

Invisible No More: How Redefining Rare Diseases Can Advance Health Equity.

Journal of clinical pharmacology·2026

Related Experiment Video

Updated: Sep 14, 2025

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.0K

State-of-the-Art on Model-Informed Drug Development Approaches for Pediatric Rare Diseases.

Rajesh Krishna1, Amitava Mitra2, Matthew L Zierhut1

  • 1Certara Scientific Innovation, Certara USA, Inc, Radnor, Pennsylvania, USA.

CPT: Pharmacometrics & Systems Pharmacology
|July 23, 2025
PubMed
Summary

Model-Informed Drug Development (MIDD) uses quantitative methods to overcome challenges in developing drugs for pediatric rare diseases. These approaches optimize dosing, support data extrapolation, and enable efficient, ethical clinical trials for children.

Keywords:
caregiver‐reported outcomesmodel‐informed drug developmentpediatricsquantitative medicinerandomized clinical trialsrare diseases

More Related Videos

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery
12:40

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Published on: May 19, 2018

10.4K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.7K

Related Experiment Videos

Last Updated: Sep 14, 2025

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.0K
Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery
12:40

Using Human Induced Pluripotent Stem Cell-derived Hepatocyte-like Cells for Drug Discovery

Published on: May 19, 2018

10.4K
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

9.7K

Area of Science:

  • Pharmacometrics and Quantitative Pharmacology
  • Pediatric Drug Development
  • Rare Disease Therapeutics

Background:

  • Pediatric rare diseases pose significant hurdles for drug development, including small patient numbers and limited natural history data.
  • Traditional clinical trial designs face ethical and logistical challenges in pediatric rare disease research.
  • Model-Informed Drug Development (MIDD) offers a quantitative framework to address these complexities.

Purpose of the Study:

  • To review current Model-Informed Drug Development (MIDD) approaches for pediatric rare disease therapeutics.
  • To highlight how MIDD facilitates dose optimization and data extrapolation in pediatric drug development.
  • To discuss the role of MIDD in enabling efficient and ethical clinical trial strategies for rare pediatric conditions.

Main Methods:

  • Review of state-of-the-art MIDD methodologies, including population pharmacokinetic/pharmacodynamic (PK/PD) modeling.
  • Application of physiologically based pharmacokinetic (PBPK) modeling and disease progression modeling.
  • Integration of Bayesian trial designs and real-world data for enhanced decision-making.

Main Results:

  • MIDD approaches effectively support dose optimization for pediatric rare disease treatments.
  • Extrapolation of data from adult or other pediatric populations is facilitated by MIDD.
  • Case studies demonstrate increasing regulatory acceptance of MIDD in pediatric rare disease submissions.

Conclusions:

  • MIDD is a crucial paradigm for accelerating the development of safe and effective treatments for children with rare diseases.
  • Technological and regulatory advancements are driving the expansion of MIDD applications in this field.
  • Future opportunities exist to further enhance the impact of MIDD on pediatric rare disease therapeutics.